(S)-2-(3-amino-2-oxopyrrolidin-1-yl)acetamide | 1013920-72-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-(3-amino-2-oxopyrrolidin-1-yl)acetamide
• 英文别名: 2-[(3S)-3-amino-2-oxopyrrolidin-1-yl]acetamide
• CAS: 1013920-72-3
• 化学式: C₆H₁₁N₃O₂
• 分子量: 157.172
• InChiKey: FBJIWPIYHPWFTJ-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  89.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl 5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate 、 (S)-2-(3-amino-2-oxopyrrolidin-1-yl)acetamide 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (Z)-5-[5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ((S)-1-carbamoylmethyl-2-oxo-pyrrolidin-3-yl)amide
  参考文献：
  名称：

  WO2008/33562

  摘要：

  公开号：
• 作为产物：
  描述：

  N-[(3s)-1-(2-amino-2-oxoethyl)-2-oxo-3-pyrrolidinyl]carbamic acid 1,1-dimethylethyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (S)-2-(3-amino-2-oxopyrrolidin-1-yl)acetamide
  参考文献：
  名称：

  WO2008/33562

  摘要：

  公开号：

文献信息

• Kinase inhibitor compounds
  申请人：Liang Congxin

  公开号：US20090076005A1

  公开（公告）日：2009-03-19

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

  这项发明涉及化合物、包含这些化合物的组合物，以及使用这些化合物和化合物组合物的方法。本文描述的化合物、组合物和方法可用于治疗激酶介导的过程，并治疗疾病和疾病症状，特别是那些由特定激酶酶介导的症状。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020095215A1

  公开（公告）日：2020-05-14

  A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明的化合物具有式（I），其中Ar1，R21，R23，R24，R25，R26，R27，A，X，Y和W如本文所定义。本发明的化合物是造血前列腺素D合酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉营养不良。因此，该发明进一步涉及包含本发明化合物的药物组合物。该发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• KINASE INHIBITOR COMPOUNDS
  申请人：Liang Congxin

  公开号：US20120115866A1

  公开（公告）日：2012-05-10

  The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

  本发明涉及化合物、含有这些化合物的组合物以及使用这些化合物和组合物的方法。本文所描述的化合物、组合物和方法可用于治疗激酶介导的过程，以及治疗疾病和疾病症状，特别是那些由某些激酶酶介导的疾病和疾病症状的治疗。
• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Ltd

  公开号：EP3877384A1

  公开（公告）日：2021-09-15
• Chemical Compounds
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20220009918A1

  公开（公告）日：2022-01-13

  A compound of formula (I), wherein Ar 1 , R 21 , R 23 , R 24 , R 25 , R 26 , R 27 , A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.